Improved transplantation outcome by epigenetic changes

Transplant Immunology

Volumn 23, Issue 3, 2010, Pages 104-110

  Schildberg, Frank A ^a,b   Hagmann, Cristina A ^a,b   Böhnert, Volker ^b   Tolba, René H ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

DNA methyltransferase (DNMT); Epigenetic changes; Histone deacetylase (HDAC); Immunosuppression; Transplantation; Venous systemic oxygen persufflation (VSOP)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DNA METHYLTRANSFERASE; FR 276457; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; OXYGEN; TACROLIMUS; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN RECOGNITION; B LYMPHOCYTE; DISEASE MODEL; DRUG MECHANISM; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; GENETIC POLYMORPHISM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; METHYLATION; MOLECULAR MECHANICS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROMOTER REGION; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; GRAFT REJECTION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; OXYGEN; TRANSPLANTATION IMMUNOLOGY;

EID: 77953916635     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.05.001     Document Type: Review

References (90)

1. Williams A., Peh C.A., Elliott T. The cell biology of MHC class I antigen presentation. Tissue Antigens 2002, 59:3-17.
2. Marrack P., Kappler J. Positive selection of thymocytes bearing alpha beta T cell receptors. Curr Opin Immunol 1997, 9:250-255.
3. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
4. Matzinger P. An innate sense of danger. Semin Immunol 1998, 10:399-415.
5. Barchet W., Wimmenauer V., Schlee M., Hartmann G. Accessing the therapeutic potential of immunostimulatory nucleic acids. Curr Opin Immunol 2008, 20:389-395.
6. Starzl T.E. History of clinical transplantation. World J Surg 2000, 24:759-782.
7. [cited 2009 06 Oct]. http://www.eurotransplant.nl.
8. [cited 2009 06 Oct]. http://www.eltr.org.
9. [cited 2009 06 Oct]. http://www.unos.org.
10. Wei L., Hata K., Doorschodt B.M., Buttner R., Minor T., Tolba R.H. Experimental small bowel preservation using Polysol: a new alternative to University of Wisconsin solution, Celsior and histidine-tryptophan-ketoglutarate solution?. World J Gastroenterol 2007, 13:3684-3691.
11. Bessems M., Doorschodt B.M., van Vliet A.K., van Gulik T.M. Improved rat liver preservation by hypothermic continuous machine perfusion using polysol, a new, enriched preservation solution. Liver Transpl 2005, 11:539-546.
12. Rauen U., Klempt S., de Groot H. Histidine-induced injury to cultured liver cells, effects of histidine derivatives and of iron chelators. Cell Mol Life Sci 2007, 64:192-205.
13. Yamauchi J., Schramm R., Richter S., Vollmar B., Menger M.D., Minor T. Improvement of microvascular graft equilibration and preservation in non-heart-beating donors by warm preflush with streptokinase. Transplantation 2003, 75:449-453.
14. Belzer F.O., Southard J.H. Principles of solid-organ preservation by cold storage. Transplantation 1988, 45:673-676.
15. Southard J.H., Belzer F.O. Organ preservation. Annu Rev Med 1995, 46:235-247.
16. Morariu A.M., Vd Plaats A., W, V.O., NA T.H., Leuvenink H.G., Graaff R., Ploeg R.J., Rakhorst G. Hyperaggregating effect of hydroxyethyl starch components and University of Wisconsin solution on human red blood cells: a risk of impaired graft perfusion in organ procurement?. Transplantation 2003, 76:37-43.
17. Gok M.A., Shenton B.K., Buckley P.E., Peaston R., Cornell C., Soomro N., Jaques B.C., Manas D.M., Talbot D. How to improve the quality of kidneys from non-heart-beating donors: a randomised controlled trial of thrombolysis in non-heart-beating donors. Transplantation 2003, 76:1714-1719.
18. Reddy S., Zilvetti M., Brockmann J., McLaren A., Friend P. Liver transplantation from non-heart-beating donors: current status and future prospects. Liver Transpl 2004, 10:1223-1232.
19. Kootstra G., Kievit J.K., Heineman E. The non heart-beating donor. Br Med Bull 1997, 53:844-853.
20. Abt P.L., Desai N.M., Crawford M.D., Forman L.M., Markmann J.W., Olthoff K.M., Markmann J.F. Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004, 239:87-92.
21. Abt P., Crawford M., Desai N., Markmann J., Olthoff K., Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003, 75:1659-1663.
22. Minor T., Klauke H., Isselhard W. Resuscitation of cadaveric livers from non-heart-beating donors after warm ischemic insult: a novel technique tested in the rat. Experientia 1996, 52:661-664.
23. Minor T., Saad S., Nagelschmidt M., Kotting M., Fu Z., Paul A., Isselhard W. Successful transplantation of porcine livers after warm ischemic insult in situ and cold preservation including postconditioning with gaseous oxygen. Transplantation 1998, 65:1262-1264.
24. Treckmann J., Minor T., Saad S., Ozcelik A., Malago M., Broelsch C.E., Paul A. Retrograde oxygen persufflation preservation of human livers: a pilot study. Liver Transpl 2008, 14:358-364.
25. Arakelov A., Lakkis F.G. The alloimmune response and effector mechanisms of allograft rejection. Semin Nephrol 2000, 20:95-102.
26. Warrens A.N., Lombardi G., Lechler R.I. Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 1994, 2:103-107.
27. Lechler R.I., Batchelor J.R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982, 155:31-41.
28. Caballero A., Fernandez N., Lavado R., Bravo M.J., Miranda J.M., Alonso A. Tolerogenic response: allorecognition pathways. Transpl Immunol 2006, 17:3-6.
29. Orosz C.G., Pelletier R.P. Chronic remodeling pathology in grafts. Curr Opin Immunol 1997, 9:676-680.
30. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
31. Gummert J.F., Ikonen T., Morris R.E. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999, 10:1366-1380.
32. Akbar S., Minor T. Significance and molecular targets of protein kinase A during cAMP-mediated protection of cold stored liver grafts. Cell Mol Life Sci 2001, 58:1708-1714.
33. Mehta T.K., Hoque M.O., Ugarte R., Rahman M.H., Kraus E., Montgomery R., Melancon K., Sidransky D., Rabb H. Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury during transplantation. Transplant Proc 2006, 38:3420-3426.
34. Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem Sci 2007, 32:389-397.
35. Mellor J. Dynamic nucleosomes and gene transcription. Trends Genet 2006, 22:320-329.
36. Varga-Weisz P.D., Becker P.B. Regulation of higher-order chromatin structures by nucleosome-remodelling factors. Curr Opin Genet Dev 2006, 16:151-156.
37. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 2006, 75:243-269.
38. Jin J., Cai Y., Li B., Conaway R.C., Workman J.L., Conaway J.W., Kusch T. In and out: histone variant exchange in chromatin. Trends Biochem Sci 2005, 30:680-687.
39. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9:3578-3588.
40. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009, 9:91-105.
41. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
42. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., Ferrara J.L. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A 2004, 101:3921-3926.
43. Leng C., Gries M., Ziegler J., Lokshin A., Mascagni P., Lentzsch S., Mapara M.Y. Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp Hematol 2006, 34:776-787.
44. Reddy P., Sun Y., Toubai T., Duran-Struuck R., Clouthier S.G., Weisiger E., Maeda Y., Tawara I., Krijanovski O., Gatza E., Liu C., Malter C., Mascagni P., Dinarello C.A., Ferrara J.L. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008, 118:2562-2573.
45. Bohmig G.A., Krieger P.M., Saemann M.D., Ullrich R., Karimi H., Wekerle T., Muhlbacher F., Zlabinger G.J. Stable prodrugs of n-butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination. Transpl Immunol 1999, 7:221-227.
46. Kinugasa F., Nagatomi I., Nakanishi T., Noto T., Mori H., Matsuoka H., Sudo Y., Mutoh S. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol 2009, 21:198-202.
47. Kinugasa F., Yamada T., Noto T., Matsuoka H., Mori H., Sudo Y., Mutoh S. Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol Pharm Bull 2008, 31:1723-1726.
48. Hellebrekers D.M., Castermans K., Vire E., Dings R.P., Hoebers N.T., Mayo K.H., Oude Egbrink M.G., Molema G., Fuks F., van Engeland M., Griffioen A.W. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006, 66:10770-10777.
49. Moon C., Kim S.H., Park K.S., Choi B.K., Lee H.S., Park J.B., Choi G.S., Kwan J.H., Joh J.W., Kim S.J. Use of epigenetic modification to induce FOXP3 expression in naive T cells. Transplant Proc 2009, 41:1848-1854.
50. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
51. Singal R., Ginder G.D. DNA methylation. Blood 1999, 93:4059-4070.
52. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., Funke R., Gage D., Harris K., Heaford A., Howland J., Kann L., Lehoczky J., LeVine R., McEwan P., McKernan K., Meldrim J., Mesirov J.P., Miranda C., Morris W., Naylor J., Raymond C., Rosetti M., Santos R., Sheridan A., Sougnez C., Stange-Thomann N., Stojanovic N., Subramanian A., Wyman D., Rogers J., Sulston J., Ainscough R., Beck S., Bentley D., Burton J., Clee C., Carter N., Coulson A., Deadman R., Deloukas P., Dunham A., Dunham I., Durbin R., French L., Grafham D., Gregory S., Hubbard T., Humphray S., Hunt A., Jones M., Lloyd C., McMurray A., Matthews L., Mercer S., Milne S., Mullikin J.C., Mungall A., Plumb R., Ross M., Shownkeen R., Sims S., Waterston R.H., Wilson R.K., Hillier L.W., McPherson J.D., Marra M.A., Mardis E.R., Fulton L.A., Chinwalla A.T., Pepin K.H., Gish W.R., Chissoe S.L., Wendl M.C., Delehaunty K.D., Miner T.L., Delehaunty A., Kramer J.B., Cook L.L., Fulton R.S., Johnson D.L., Minx P.J., Clifton S.W., Hawkins T., Branscomb E., Predki P., Richardson P., Wenning S., Slezak T., Doggett N., Cheng J.F., Olsen A., Lucas S., Elkin C., Uberbacher E., Frazier M. Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
53. Yoder J.A., Walsh C.P., Bestor T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997, 13:335-340.
54. Weber M., Davies J.J., Wittig D., Oakeley E.J., Haase M., Lam W.L., Schubeler D. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005, 37:853-862.
55. Heard E., Clerc P., Avner P. X-chromosome inactivation in mammals. Annu Rev Genet 1997, 31:571-610.
56. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007, 447:425-432.
57. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16:6-21.
58. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97.
59. Balch C., Yan P., Craft T., Young S., Skalnik D.G., Huang T.H., Nephew K.P. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 2005, 4:1505-1514.
60. Kroger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology Am Soc Hematol Educ Program 2008, 2008:60-67.
61. Valinluck V., Tsai H.H., Rogstad D.K., Burdzy A., Bird A., Sowers L.C. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 2004, 32:4100-4108.
62. Pratt J.R., Parker M.D., Affleck L.J., Corps C., Hostert L., Michalak E., Lodge J.P. Ischemic epigenetics and the transplanted kidney. Transplant Proc 2006, 38:3344-3346.
63. Parker M.D., Chambers P.A., Lodge J.P., Pratt J.R. Ischemia-reperfusion injury and its influence on the epigenetic modification of the donor kidney genome. Transplantation 2008, 86:1818-1823.
64. Dery M.A., Michaud M.D., Richard D.E. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005, 37:535-540.
65. Bardos J.I., Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta 2005, 1755:107-120.
66. Fandrey J., Gorr T.A., Gassmann M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc Res 2006, 71:642-651.
67. Kaelin W.G. Proline hydroxylation and gene expression. Annu Rev Biochem 2005, 74:115-128.
68. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002, 16:1466-1471.
69. Koumenis C., Alarcon R., Hammond E., Sutphin P., Hoffman W., Murphy M., Derr J., Taya Y., Lowe S.W., Kastan M., Giaccia A. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001, 21:1297-1310.
70. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett 2008, 266:6-11.
71. Pappa A., Franco R., Schoneveld O., Galanis A., Sandaltzopoulos R., Panayiotidis M.I. Sulfur-containing compounds in protecting against oxidant-mediated lung diseases. Curr Med Chem 2007, 14:2590-2596.
72. Wachsman J.T. DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 1997, 375:1-8.
73. Fischer J.H., Czerniak A., Hauer U., Isselhard W. A new simple method for optimal storage of ischemically damaged kidneys. Transplantation 1978, 25:43-49.
74. Isselhard W., Berger M., Denecke H., Witte J., Fischer J.H., Molzberger H. Metabolism of canine kidneys in anaerobic ischemia and in aerobic ischemia by persufflation with gaseous oxygen. Pflugers Arch 1972, 337:87-106.
75. Minor T., Klauke H., Nagelschmidt M., Isselhard W. Reduction of proteolysis by venous-systemic oxygen persufflation during rat liver preservation and improved functional outcome after transplantation. Transplantation 1997, 63:365-368.
76. Granger D.N. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 1988, 255:H1269-H1275.
77. Song S.W., Tolba R.H., Yonezawa K., Manekeller S., Minor T. Exogenous superoxide dismutase prevents peroxynitrite-induced apoptosis in non-heart-beating donor livers. Eur Surg Res 2008, 41:353-361.
78. Lauschke H., Kotting M., Akbar S., Minor T. Use of taurine as antioxidant in resuscitating livers from non-heart-beating donors by gaseous oxygen persufflation. J Invest Surg 2003, 16:7-11.
79. Jaeschke H., Smith C.W. Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997, 61:647-653.
80. Martinez-Mier G., Toledo-Pereyra L.H., Ward P.A. Adhesion molecules in liver ischemia and reperfusion. J Surg Res 2000, 94:185-194.
81. Menger M.D., Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996, 83:588-601.
82. Lauschke H., Olschewski P., Tolba R., Schulz S., Minor T. Oxygenated machine perfusion mitigates surface antigen expression and improves preservation of predamaged donor livers. Cryobiology 2003, 46:53-60.
83. Halloran P.F., Broski A.P., Batiuk T.D., Madrenas J. The molecular immunology of acute rejection: an overview. Transpl Immunol 1993, 1:3-27.
84. Granger A., Abdullah I., Huebner F., Stout A., Wang T., Huebner T., Epstein J.A., Gruber P.J. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008, 22:3549-3560.
85. Stoffels B., Tolba R.H., Schildberg F.A., Wolff M., Lauschke H., Kalff J.C., Hirner A. Komplikationen durch immunsuppressive Therapie nach Lebertransplantation-eine retrospektive 12-Jahres-Analyse des Transplantationszentrums Bonn. Chir Gastroenterol 2008, 24:226-233.
86. Chang C.C., Campoli M., Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 2005, 93:189-234.
87. Setiadi A.F., David M.D., Seipp R.P., Hartikainen J.A., Gopaul R., Jefferies W.A. Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol Cell Biol 2007, 27:7886-7894.
88. Krishnan N., Buchanan P.M., Dzebisashvili N., Xiao H., Schnitzler M.A., Brennan D.C. Monozygotic transplantation: concerns and opportunities. Am J Transplant 2008, 8:2343-2351.
89. Endres M., Meisel A., Biniszkiewicz D., Namura S., Prass K., Ruscher K., Lipski A., Jaenisch R., Moskowitz M.A., Dirnagl U. DNA methyltransferase contributes to delayed ischemic brain injury. J Neurosci 2000, 20:3175-3181.
90. Ellinger J., Kahl P., von der Gathen J., Rogenhofer S., Heukamp L.C., Gutgemann I., Walter B., Hofstadter F., Buttner R., Muller S.C., Bastian P.J., von Ruecker A. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.